INDICATIONS
Clofarabine and cytarabine is an alternative treatment for patients with de novo, relapsed, or refractory acute myeloid leukemia. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] The regimen has also been used as a conditioning regimen for allogenic bone marrow transplantation. 13 Current guidelines recommend clofarabine and granulocyte colony stimulating factor with or without cytarabine, and/ or idarubicin for aggressive therapy in appropriate patients with relapsed or refractory disease. 14
DRUG PREPARATION
Follow institutional policies for preparation of hazardous medications when preparing and dispensing clofarabine and cytarabine. A. Clofarabine 1. Use clofarabine injection 1 mg/mL. 2. Filter through a 0.2 micron filter into the final container. 3. Dilute in 250 to 1000 mL of 0.9% sodium chloride (NS) or 5% dextrose in water (D5W) to a final concentration of 0.15 to 0.4 mg/mL. B. Cytarabine 1. Use cytarabine injection 20 mg/mL, 100 mg/mL, or cytarabine powder for injection. 2. Reconstitute the powder with NS, D5W or sterile water for injection to a concentration of 20 mg/mL, 50 mg/mL, or 100 mg/mL. 3. Dilute in 250 to 1000 mL NS or D5W. 4. To avoid potential toxicity, benzyl alcohol preserved diluents should be avoided for the reconstitution of cytarabine. 
DRUG ADMINISTRATION

SUPPORTIVE CARE A. Acute and Delayed Emesis Prophylaxis:
The clofarabine and cytarabine regimen is predicted to cause acute emesis in 30% to 90% of patients. [15] [16] [17] [18] However, nausea was reported in only one of the trials reviewed, with 3% of patients reporting grade 3 or 4 nausea. 3 Prophylactic antiemetic therapy with a serotonin antagonist is recommended, 16-18 but may not be required in all patients. One group suggests addition of a neurokinin (NK 1 ) antagonist may be appropriate in some patients. 16 One of the following regimens given 30 minutes prior to therapy is recommended: If a neurokinin antagonist is used, one of the following regimens is recommended: The antiemetic therapy should continue for at least 3 days after the last dose of clofarabine and cytarabine. A meta-analysis of several trials of serotonin antagonists recommends against prolonged (greater than 24 hours) use of these agents, making a steroid, or steroid and dopamine antagonist combination, most appropriate for follow-up therapy. 19 One of the following regimens is recommended, beginning on day 6: Patients who experience significant nausea or vomiting with one of these regimens should receive an agent from a different pharmacologic category. [15] [16] [17] [18] There is no evidence that substituting granisetron for ondansetron in subsequent treatment cycles or increasing the dose, even to very high doses, is effective. This approach is not recommended. [20] [21] [22] [23] [24] B. Breakthrough Nausea and Vomiting [15] [16] [17] [18] : Patients should receive a prescription for an antiemetic to treat breakthrough nausea. One of the following regimens is recommended: Patients who do experience significant nausea or vomiting with one of these regimens should receive an agent from a different pharmacologic category. [15] [16] [17] [18] There is no evidence that substituting granisetron for ondansetron in subsequent treatment cycles or increasing the dose, even to very high doses, is effective. This approach is not recommended. [20] [21] [22] [23] [24] C. Hematopoietic Growth Factors: Accepted practice guidelines and pharmaco economic analysis suggest that an antineoplastic regimen have a 20% or higher incidence of febrile neutropenia before prophylactic use of colony stimulating factors (CSFs) is warranted. For regimens with an incidence of febrile neutropenia between 10% and 20%, use of CSFs should be considered. For regimens with an incidence of febrile neutropenia less than 10%, routine prophylactic use of CSFs is not recommended. 25, 26 Severe (grade 3 or 4) neutropenia was reported in 11% of patients in the clofarabine and cytarabine trials reviewed; febrile neutropenia was reported in 47% of patients. 2 Usually prophylactic use of CSFs is recommended in regimens that cause febrile neutropenia in greater than 20% of patients; however current guidelines for using prophylactic growth factors in patients with acute myeloid leukemia warn that use of CSFs following induction therapy may interfere with interpretation of the post-remission bone marrow biopsy results. 14
MAJOR TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http:/ctep.info.nih.gov). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities, but make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent c. Serum creatinine less than 30 mL/min, do not give drug. 29 d. Adjustment may be required, but no guideline is available. 30 e. No adjustment is required. 31 B. Liver Function 1. Clofarabine: Bilirubin greater than 3 times the ULN, give 50% of dose. 27 
Cytarabine:
a. Bilirubin greater than 2 mg/dL, give 50% of dose. 32 b. Any elevation in transaminases, give 50% of dose. 33,34 c. No information is available. 30 
